Core Viewpoint - The article discusses the Warburg effect, highlighting how cancer cells exhibit increased glycolysis even in the presence of oxygen, leading to enhanced lactate production and cancer progression. Recent research has uncovered the molecular mechanisms behind this phenomenon, specifically focusing on the role of lactate in activating the ERK signaling pathway through a lactylation-phosphorylation loop involving the enzyme GCN5 [2][3][5][7]. Group 1 - The Warburg effect describes the phenomenon where cancer cells maintain high levels of glycolysis despite sufficient oxygen, which is contrary to normal cellular metabolism [2]. - A recent study published in Nature Chemical Biology reveals that lactate promotes tumor progression by inducing lactylation of the ERK protein, enhancing the RAS-ERK signaling pathway [3][5]. - The study identifies GCN5 as the lactyltransferase responsible for ERK lactylation, which is activated by ERK phosphorylation, creating a positive feedback loop that amplifies lactate-driven cancer progression [5][7]. Group 2 - The research demonstrates that lactate-induced ERK lactylation weakens its interaction with MEK, promoting ERK dimerization and activation, which further drives cancer development [5][7]. - A cell-penetrating peptide was developed to specifically inhibit ERK lactylation, showing potential in suppressing tumor growth in KRAS mutant cancer models [5][7].

Core Insights - Lung cancer is a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases, and lung adenocarcinoma (LUAD) being the most common subtype. The five-year survival rate for lung adenocarcinoma patients is below 26% [2] - The study published in Cell Discovery reveals that ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing the degradation of ACSL4 in lung adenocarcinoma, identifying a key regulatory factor in the resistance to ferroptosis and proposing a new strategy for cancer treatment based on ferroptosis [3][8] Group 1: Ferroptosis and Cancer Treatment - Ferroptosis is a regulated form of cell death characterized by the accumulation of reactive oxygen species (ROS), lipid peroxides, and increased levels of divalent iron (Fe2+), showing significant effectiveness in overcoming resistance to traditional cancer therapies [5] - The study indicates that ferroptosis significantly increases lactate accumulation and subsequent protein lactylation, which contributes to the resistance of lung adenocarcinoma cells to ferroptosis [6] Group 2: Key Findings of the Research - SUMO2-K11 lactylation is identified as a critical factor determining the resistance to ferroptosis in lung adenocarcinoma, as it weakens the interaction between SUMO2 and ACSL4, promoting ACSL4 degradation and disrupting lipid metabolism [6][8] - AARS1 is recognized as the lactylation transferase for SUMO2-K11la, while HDAC1 acts as the de-lactylase. The research team developed a cell-penetrating peptide that specifically inhibits SUMO2-K11la, enhancing ferroptosis and increasing the sensitivity of lung adenocarcinoma to the chemotherapy drug cisplatin [6][8]